Patent
Methods and compositions for targeting specific tissue
Yuet Wai Kan,Noriyuki Kasahara +1 more
Reads0
Chats0
TLDR
In this paper, a vehicle for preferentially targeting the delivery of a substance to a sub-population of mammalian cells is described, which includes a targeting moiety capable of associating with or forming an envelope defining a compartment that contains the substance to be delivered to the subpopulation of cells.Abstract:
Methods and compositions for preferentially targeting the delivery of a substance to a sub-population of mammalian cells. The vehicle of the invention includes a targeting moiety capable of associating with or forming an envelope defining a compartment that contains the substance to be delivered to the sub-population of cells. The targeting moiety also contains a domain capable of interacting with a member of a binding pair located on the surface of the sub-population of cells.read more
Citations
More filters
Patent
Binding domain-immunoglobulin fusion proteins
TL;DR: In this paper, binding domain-immunoglobulin fusion proteins are defined as proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, and can be recombinantly produced at high expression levels.
Patent
Binding constructs and methods for use thereof
TL;DR: In this article, binding domain-immunoglobulin fusion proteins are defined, which can be recombinantly produced at high expression levels and are capable of ADCC and/or CDC while occurring predominantly as polypeptides compromised in their ability to form disulfide-linked multimers.
Patent
Single-chain multivalent binding proteins with effector function
Peter Armstrong Thompson,Jeffrey A. Ledbetter,Martha Hayden-Ledbetter,Laura Sue Grosmaire,Robert Bader,William Brady +5 more
TL;DR: In this article, multivalent binding peptides, including bi-specific binding peptide, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using these peptides to treat or prevent a variety of diseases, disorders or conditions, and to ameliorate at least one symptom associated with such a disease, disorder or condition.
Patent
Nucleic acids and proteins from streptococcus groups a & b
TL;DR: In this paper, the authors provided proteins from group B streptococcus and group A staphylococcus pyogenes, including amino acid sequences and corresponding nucleotide sequences, for vaccines, immunogenic compositions, and diagnostics.
Patent
Neisseria meningitidis antigens and compositions
Claire M. Fraser,Cesira Galeotti,G. Grandi,Erin Hickey,V. Masignani,Maria Rosa Mora,Jeremy Petersen,Mariagrazia Pizza,R. Rappuoli,Giulo Ratti,Vincenzo Scarlato,Maria Scarselli,Hervé Tettelin,Craig J. Venter +13 more
TL;DR: This article provided proteins from Neisseria meningitidis, including the amino acid sequences and corresponding nucleotide sequences, which are predicted to be useful antigens for vaccines and/or diagnostics.
References
More filters
Journal ArticleDOI
Cloning and expression of the human erythropoietin gene.
Fu-Kuen Lin,Sidney Vaughn Suggs,C H Lin,J K Browne,Richard W. Smalling,Joan C. Egrie,Kenneth Chen,G. M. Fox,F Martin,Z Stabinsky +9 more
TL;DR: The human erythropoietin gene has been isolated from a genomic phage library by using mixed 20-mer and 17-mer oligonucleotide probes and encodes a 27-amino acid signal peptide and a 166-AMino acid mature protein with a calculated Mr of 18,399.
Journal ArticleDOI
Isolation and characterization of genomic and cDNA clones of human erythropoietin
Kenneth Jacobs,Charles B. Shoemaker,Richard Rudersdorf,Suzanne D. Neill,Randal J. Kaufman,Allan Mufson,Jasbir Seehra,Simon S. Jones,Rodney M. Hewick,Edward Fritsch,Makoto Kawakita,Tomoe Shimizu,Takaji Miyake +12 more
TL;DR: The cloning of the human erythropoietin gene and the expression of an erythrocytes cDNA clone in a transient mammalian expression system to yield a secreted product with biological activity are described.
Journal ArticleDOI
Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor.
Jing-Po Li,Alan D. D'Andrea,Alan D. D'Andrea,Alan D. D'Andrea,Harvey F. Lodish,David Baltimore +5 more
TL;DR: It is suggested that through direct binding to Epo-R, gp55 can stimulate the receptor and by-pass the normal requirement for Epo, causing prolonged proliferation of infected erythroid cells, which could be the first step of leukaemogenesis induced by Friend virus.
Journal ArticleDOI
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.
David J.A. Evans,Jane A. McKeating,Janet Meredith,Karen L. Burke,Kersi Katrak,Ann John,Morag Ferguson,Philip D. Minor,Robin A. Weiss,Jeffrey W. Almond +9 more
TL;DR: The construction and characterization of a poliovirus antigen chimaera containing an epitope from the transmembrane glycoprotein (gp41) of human immunodeficiency virus type 1 (HIV-1) are described and it is suggested that Sabin 1 poliov virus/HIV chimaeras could offer an approach to the development of ah HIV vaccine.
Journal ArticleDOI
Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells
R A Hock,A D Miller +1 more
TL;DR: An amphotropic retroviral vectors containing either the bacterial gene for neomycin resistance or a mutant dihydrofolate reductase gene that confers resistance to methotrexate are produced and used to infect and confer drug resistance to human haematopoietic progenitor cells in vitro.